Trelagliptin

Trelagliptin
Clinical data
Trade names	Zafatek, Wedica
ATC code	None;
Identifiers
	IUPAC name 2-({6-[(3R)-3-Amino-1-piperidinyl]-3-methyl-2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl}methyl)-4-fluorobenzonitrile;
CAS Number	865759-25-7;
PubChem CID	15983988;
DrugBank	DB15323;
ChemSpider	13115365;
UNII	Q836OWG55H;
KEGG	D10178;
CompTox Dashboard (EPA)	DTXSID00235678 ;
Chemical and physical data
Formula	C18H20FN5O2
Molar mass	357.389 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Cn1c(=O)cc(n(c1=O)Cc2cc(ccc2C#N)F)N3CCC[C@H](C3)N;
	InChI InChI=1S/C18H20FN5O2/c1-22-17(25)8-16(23-6-2-3-15(21)11-23)24(18(22)26)10-13-7-14(19)5-4-12(13)9-20/h4-5,7-8,15H,2-3,6,10-11,21H2,1H3/t15-/m1/s1; Key:IWYJYHUNXVAVAA-OAHLLOKOSA-N;

Trelagliptin (trade name Trelaglip, Zafatek) is a pharmaceutical drug used for the treatment of type 2 diabetes (diabetes mellitus).Trelagliptin is an orally active dipeptidyl peptidase (DPP)-4 inhibitor developed by Takeda and approved in Japan and India for the treatment of type 2 diabetes mellitus. Zuventus Healthcare introduced Trelagliptin in India (2025) under the brand name Trelaglip®.